Sunshine Biopharma Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110,596 |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M |
| Cost of revenue | $24.1M | $24.2M | $15.8M | $2.6M | $117,830 |
| Cash from operations | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M |
| Capital expenditure | $174,491 | $1.7M | $82,251 | $193,982 | $0 |
| Free cash flow | -$5.5M | -$14.2M | -$8.9M | -$5.4M | -$1.8M |
| Share repurchases | $0 | $3.1M | $541,143 | — | — |
| Impairments | — | — | $0 | $18.3M | $0 |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M |
Shares outstanding 5.0M · Free float 23.5%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.